Cognition Therapeutics Completes Enrollment In Phase 2 SHIMMER Study Of CT1812 In Mild-To-Moderate Dementia With Lewy Bodies, Top-line Results Are Expected In 2H Of 2024 After The Last Participants Have Completed Six Months Of Treatment
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cognition Therapeutics Completes Enrollment In Phase 2 SHIMMER Study Of CT1812 In Mild-To-Moderate Dementia With Lewy Bodies, Top-line Results Are Expected In 2H Of 2024 After The Last Participants Have Completed Six Months Of Treatment